iLIVER is an open access English journal in the field of hepatology, hosted by the Ministry of Education of the People's Republic of China and Tsinghua University, published by Tsinghua University Press, and distributed globally by Elsevier. iLIVER aims to present and disseminate the innovations and practical achievements in the field of hepatology, and to provide core academic resources for multidisciplinary physicians, experts and scholars engaged in the basic, preventive, clinical, translational science and medical interdisciplinary research of the hepatobiliary system.
iLIVER publishes Original article, Meta-analysis, Review, Consensus and Practice Guideline, Editorial, Correspondence, Short communication concerning clinical medicine, translational medicine, basic medicine and public health in the field of hepatobiliary system.
The scope includes but is not limited to the following aspects:
Studies on the structure, function and regulation mechanism of liver;
Basic studies on hepatobiliary diseases, including etiology, pathogenesis, pathophysiology and prevention strategies;
Prevention, diagnosis, treatment, rehabilitation and chronic disease management of hepatobiliary diseases;
Studies on public health related to epidemiology, prevention, monitoring and health policy of hepatobiliary diseases;
Translational science related to liver health;
Application of data and intelligent technology in the field of hepatology;
Clinical drug trials and medical device clinical trials related to hepatobiliary diseases;
Interdisciplinary research focusing on hepatology.
Types of Article
Original articles are full-length reports of original research. Original articles must be no longer than 4,000 words (excluding references, table, figure legends). Structured abstracts of up to 250 words are required, structured as follows: background and aims; methods; results; conclusion. The title should with no more than 120 characters (excluding spaces). Manuscripts should contain no more than 8 figures and tables. References should not exceed a maximum of 100.
Review articles aims to provide systematic and substantial coverage of mature subjects, evaluations of progress in specified areas, and/or critical assessments of emerging technologies. Review articles are expected to be clear, concise and updated, also should include 3 to 6 key points. Review articles should be no longer than 7,000 words (excluding references). Unstructured abstracts of up to 250 words are required. The inclusion of a maximum of 8 tables and/or figures to summarize critical points is allowed. References should not exceed a maximum of 150.
Meta-analysis articles are systematic, critical assessments of current literature pertaining to clinical topics, emphasizing factors such as cause, diagnosis, prognosis, therapy, or prevention. All articles should be searched for and selected systematically for inclusion and critically evaluated, and the search and selection process should be described in the manuscript. The specific type of study or analysis should be described for each article or data source. We encourage authors of meta-analyses of clinical trials to submit the PRISMA flow diagram and checklist, authors of meta-analyses of observational studies to submit the MOOSE checklist as supplemental items. Text word limits: 5,000 words, excluding abstract, references, tables, and figures; Structured abstract: 250 words; References: 75 maximum. Tables and figures: 7 maximum.
Short communications are concise, meritorious scientific reports of novel original research that is within the journal's scope and of particular interest to the community. It should not have an abstract or subsections such as Introduction, Results or Discussion. The information of Materials and Methods could be submitted as supplementary materials if necessary. It must be less than 1,000 words (excluding table, figure legends, or references), contain no more than 1 figure or table and 10 references. The maximum number of authors is 6.
Editorials are invited opinions of recognized leaders in hepatobiliary specialties. It should be no longer than 1,500 words (including references and table or figure legends) and include no more than 1 figure or table and 9 references.
Correspondence offers novel perspectives and opinions on publications in iLIVER. Correspondence must be submitted by the end of the month in which the corresponding article was published in print (e.g., a response to an article in the March issue should be submitted by the end of March). Correspondence is usually not peer reviewed. Correspondence should be no longer than 500 words (including references and table or figure legends) and include no more than 5 references and 1 figure or table. The maximum number of authors is 2.
Consensus and Practice Guideline should be driven by a high level of evidence and describe novel diagnostic or therapeutic algorithms that are not already well-documented by other organizations or publications. Consensus meetings or Guideline committees should be convened by a high-profile, non-profit, Hepatology organization or group that ensures broad and objective input from recognized experts on the topic. The length of Practice Guideline is decided by the Editor on a case-by-case basis. Consensus should be no longer than 2,400 words (including figure, table legends) and contain no more than 2 figures or tables and 25 refere
Submission checklist
You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.
Ensure that the following items are present:
One author has been designated as the corresponding author with contact details:
• E-mail address
• Full postal address
All necessary files have been uploaded:
Manuscript:
• Include keywords
• All figures (include relevant captions)
• All tables (including titles, description, footnotes)
• Ensure all figure and table citations in the text match the files provided
• Indicate clearly if color should be used for any figures in print
